Soleno Therapeutics Inc (SLNO) Cotización

Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

Dumbest trading decision I've made in past yr was to sell SLNO when it ran from around $3 ( my cost ) to over $20 .
If I still owned it..... this post could have been from some exotic local ( although where I am is pretty nice )

Kiwi

Roller coaster for the last 6 months but the recent earnings update has been well received.

Not a good trend since the big runup

SLNO new 52 week high

Wait for the volume drop picking up on the downside only imho

Was $0.85 not long ago. With 2 Reverse Splits R/S. Huge raises at highs and falls, rinse and repeat. Blasted over 10x pasted its Reverse Split R/S price. IMO needs serious consolidation.

Took a small profit here...,Did not move down fast enough.

Great quiet move today here

A post from years back to give people an idea on what Prader Will is like for a family

Whalatane
Member Level
Re: ronpopeil post# 160
Thursday, March 14, 2019 6:57:35 PM
Post# of 293
Hi Ron ...yeah it is been a tough hold.
A friends son has Prader-Willi ...insatiable hunger is one thing ...its the violent outburst and aggressive behavior when they are denied food , that make life very difficult for these families and their care givers.

My friend would lock the food cabinets etc ...son would then trash the house ...finally had to be institutionalized .
Kiwi

https://finance.yahoo.com/news/soleno-therapeutics-announces-proposed-public-200100341.html

Kiwi

I'll have it on the radar. Thanks.

Stop by our board with plays and alerts for real companies.

Very good recap, Walatane and wonderful for the families!
Science can be good. Not always screwed around with by the bad guys.

MG. A friend has a young son with Prader Willi . It's an awful disease . The insatiable hunger these patients experience usually requires them to be institutionalized in some form. By insatiable hunger ...you can lock all the food up in the house but if they find some dry dog food somewhere they'll start eating that .
So I had been following PW research for some time .
Covid created problems for their clinical trial.
This last trial was literally their last chance ....and results were better than expected.

Cash on hand is now very low so some form of capital raise will be necessary in coming days/ weeks ....which is why I sold my position yesterday .
This drug tho will be a major benefit for PW patients and their families .
It will require life long use ...or until something better is found ...and may enable many of these kids to live back at home , rather than the " group " home many are now in.
My current focus is on ARDX ...with a PDUFA date on Oct 17th ...feel free to post comments also on that board .

Kiwi

I'm not even going to check that figure you gave for spend. I know you're incorrect on Phase. It's Phase 3

https://soleno.life/programs/

You were early to alert but too modest in your projection :)

Good job Whalatane. Now following you.

MG

SLNO was one of the two BIG runners yesterday.

It closed up 505%, from $4.43 to $26.80!

It made all four of our five positive scans: Most Active #2, highest % Gainer #1, Highest Dollar Increase #1 and 52 Week High #1

Wow, that's impressive! So what was behind this stratospheric jump?

Soleno Therapeutics' Study Outcome Bolsters Confidence In PWS Treatment

BENZINGA 3:18 PM ET Sep-26-2023

Earlier on Tuesday, Soleno Therapeutics Inc (NASDAQ:SLNO) released top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for Prader-Willi syndrome (PWS).

Cantor Fitzgerald raised the price target on Soleno Therapeutics from $19 to $35, with an Overweight rating.

The analysts Kristen Kluska, Richard Miller, and Jason Bouvier note that the trial outcome is as good as could have been expected.

The analysts say the data suggests promising signals regarding the treatment's durability.

The analyst suggests that the Prader-Willi Syndrome (PWS) market could hold significant appeal for Soleno Therapeutics. PWS is a rare condition, but patients typically receive early diagnoses.

Additionally, considerable awareness of this drug exists within the patient and family communities, indicating a favorable environment for a potential first-to-market opportunity.

Cantor also writes that throughout the trial, the efficacy curves for the placebo and the drug consistently diverged early, never crossed paths, and exhibited increasing separation over time.

Cantor writes that the outcome opens the door to a potential New Drug Application filing, which could support a potential approval, marking the first FDA-approved drug for PWS.

The analysts still believe the Soleno Therapeutics stock remains undervalued as it is trading at roughly 1x 2029E revenue, and they model 2035E revenues of ~$1 billion.

Price Action: SLNO shares are up 507.8% at $26.75 on the last check Tuesday.

Wonderful- a real play!! Last four we looked at were essentially Pump& Dumps. Nice to see a real one!

This morning it is trailing off, but not too badly, relatively speaking. At writing SLNO is

SOLENO THERAPEUTICS INC $22.80 -4.00 (-14.93%)

As of Sep-27-202311:00:01 AM ET

Soleno has substantial 'tute ownership. And why not- it has a promising Phase Three candidate.

Institutional ownership
49.8%
Institutional mutual fund ownership
1.2%
Mutual fund ownership
0.0%
Insider ownership
2.9%
Other
46.0%

Hooray!! It took five days to identify a legitimate runner.

MG
for the $Stock*Shop*Charts*News*Option$ board

LIFW is the new rocket

I believe this is going $50+ tomorrow. Shorts are going to get into trouble. They do not need to raise cash since they have $19M+ as of June 30th. Also, they might be able to get partnership with top line results.

SLNO....should be all downhill from here. $26.61

Lol

I was long from around $2 and sold most when it doubled .
The remainder I held expecting either $10 a share on good results ...or 10c on failure .

Very surprised to see this up 500% and tempted to short some at these levels as IMHO it's very likely they will do a capital raise. .
Well tried shorting some but trade doesn't go thru as no shares available to short
Kiwi

$SLNO $30.00 break coming new highs. This is strong going higher

Could cross $30?

IM JUST GLAD I WAS LONG SLNO $ 13.00

SOLD WAY TOO EARLY, BUT EVEN HAPPIER I COULDNT SHORT THIS SQUEEZE

IF BOUGHT AT CLOSE YESTERDAY OR EARLY THIS MORNING

$60 ------$100 AH MIGHT MOVE IN THAT DIRECTION,
20,000 TO 25,000 SHARES WOULD NET CLOSE TO $400,000 NOW. WHAO


THEN RS ON THE TABLE

JUST WOW SLNO ... Now trading up 444% today .
What's the betting on a secondary offering before the open tomorrow ?
Co is probably down to around $12m cash on hand now
Kiwi

SLNO ... Now trading up 444% today .
What's the betting on a secondary offering before the open tomorrow ?
Co is probably down to around $12m cash on hand now
Kiwi

https://stockcharts.com/h-sc/ui?s=slno&p=D&yr=0&mn=6&dy=0&id=p38090673899

https://www.barchart.com/stocks/quotes/slno/technical-chart?plot=CANDLE&volume=total&data=DO&density=M&pricesOn=1&asPctChange=0&logscale=1&indicators=BBANDS(20,2);SMA(13);PTP(50);ADX(14);SMA(50);SMACD(12,26,9);RSI(14,100);ACCUM;STOSL(14,3)&sym=CNNA&grid=1&height=500&studyheight=100

https://www.barchart.com/stocks/quotes/slno/opinion

https://finance.yahoo.com/quote/slno/

Huge gap risk for SLNO down to less than $5, the next big event may be a secondary share offering.

Well I agree the PPS action today is unsustainable.
I sold all my remains shares up 383 % . I had sold down my position during Sept as I thought the stock would go to $10 if positive and 10c on failure .
So figured the loss I could live with and left that in the stock .
You are correct in that Co has burnt thru most of their cash on hand.
This was their last chance .
HOWEVER ...this is the first good news for PW patients and those that care for them in a very long time . I expect the Co will easily attract funding now and because of the drugs excellent safety profile ...quickly approved
Kiwi

You're right. Something popped up but still volume is unsustainable and hemorrhaging money like a broken fire hydrant

This was a phase 3 trial ...I'll chk ....but I've owned this Co off and on for years.
https://investors.soleno.life/static-files/2e386ed4-8927-4b9d-a56d-f002240e64e9
A friend has a child with Prader Willi. Awful disease.
This trial was the Co's last shot .
It's trading far above where I thought it would go on positive results ........Its big news in the PW community and will make taking care of these kids / teens a lot easier
Kiwi

It's only phase 1 that still has phases 2 and 3 and FDA approvial, then distribution, and then hopefully it sells it has a very long road to go and will need capital for years to come imo

This was a very high risk investment. Previous trials had failed .
If this final trial had failed the Co would have shut down .
Congrats to all those who held long into readout .
Great news for PW patients and their families
Kiwi

These dudes made over 10 times their purchase at $1.75 when wasn't.......10 million in exchange for warrants to purchase common stock upon the Company’s announcement of enrollment completion in the randomized withdrawal period of Study C602, anticipated in Q1 2023. The warrants consist of two tranches. Tranche A warrants to purchase up to 8,598,870 shares of common stock at $1.75 for a total of approximately $15 million are required to be exercised within 30 days of announcement of positive top-line data from the randomized withdrawal period of Study C602. Tranche B warrants to purchase up to 14,000,000 shares of common stock at $2.50

Shady dealings imo

Serious pump and dump imho no revs nor profit spending over $240,000,000 a year and only in phase 1 lots more spending and pretty sure see some capital raises at a lot less per share just my opinion

Genetic Disorder Focused Soleno Therapeutics' Stock Is Trading 4X Today - Here's Why?

BENZINGA
34 mins ago
Soleno Therapeutics Inc (NASDAQ:SLNO) released top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline) Extended-Release tablets for Prader-Willi syndrome (PWS).
PWS is a genetic disorder that causes obesity, intellectual disability, and shortness of height. It is characterized by constant craving for food.
The primary endpoint was the change from baseline in hyperphagia (extreme, insatiable hunger)-related behaviors as assessed by the hyperphagia questionnaire for clinical trials (HQ-CT).
Secondary endpoints included investigator assessments of participants' overall severity of illness and change in condition, as measured by Clinical Global Impression of Severity (CGI-S) and Clinical Global Impression of Improvement (CGI-I) ratings, respectively.
Hyperphagia-related behaviors markedly worsened in the placebo group compared to DCCR, represented by a statistically significant, clinically meaningful difference in mean change from baseline in the HQ-CT total score of 5.0 at week 16 (p=0.0022).
Secondary endpoints of CGI-S and CGI-I showed strong trends towards worsening in the placebo group compared to DCCR over the randomized withdrawal period (p=0.08 and 0.09), respectively.
DCCR continued to be generally well-tolerated.
Price Action: SLNO shares are up 409.3% at $22.18 during the premarket session on the last check Tuesday.

Very blessed
Hint give it away ya get twice as much

555! Long time … just got back into town. Back to reality again how was the last half of ur summer r haven’t spoke since I left

21.40 HALT!! FILLED $13.00 SOLD & REFILLED $19.09 RISK2REWARD

Good morning

Good morning LFL! Very nice!!
$SLNO

Where you been dude? Nice to see you back again.

In at $12 out at $22 first day back to trading after taking Summer off lol

Goooooooooooooooooo $SLNO

Amazing!! 🤩
$SLNO

$SLNO Wow!!! Miss these type of plays. Goodness good job everybody in this already

$SLNO $24 !!!!! GLAD I COULDNT SHORT


SHOOOOOSH

FAKE TRADER KILLING HIS PAPER CALLS